Cetuximab after Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Inclusion Criteria

• Patients must have histologically or cytologically confirmed HNSCC
• Measurable disease by scans- at least one measurable lesion
• Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy
• Patients must have a performance status (PS) of 0-2
• Patients must be >= 18 years old
• Participant is willing and able to comply with the protocol for the duration of the study
• Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document

Exclusion Criteria

• Prior treatment with cetuximab or prior therapy that specifically and directly targets the EGFR pathway in the last five (5) years
• Prior allergic reaction to cetuximab
• History of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab
• Patients receiving any other investigational agents
• Patient is on medications that need to be continued and that might interact with cetuximab
• Any uncontrolled condition, which in the opinion of the investigator, would interfere in the safe and timely completion of study treatment and procedures
• Participant with a history of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on screening chest imaging
• Any of the following conditions: * Serious or non-healing wound, ulcer, or bone fracture at the discretion of treating physician * History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days of study enrollment * History of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study enrollment * History of myocardial infarction, ventricular arrhythmia, stable/unstable angina, -symptomatic congestive heart failure, coronary/peripheral artery bypass graft or stenting or other significant cardiac disease within 6 months prior to study enrollment * History of arterial or venous thrombosis/thromboembolic event, including pulmonary embolism within 6 months of study enrollment * Any condition requiring the use of immunosuppression, excluding rheumatologic conditions treated with stable doses of corticosteroids
• Pregnancy, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment